Drugs Made In America Acquisition Corp. (NASDAQ:DMAA – Get Free Report) was the recipient of a significant decline in short interest during the month of April. As of April 30th, there was short interest totaling 103,808 shares, a decline of 92.9% from the April 15th total of 1,465,993 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average trading volume of 163,128 shares, the short-interest ratio is currently 0.6 days.
Institutional Trading of Drugs Made In America Acquisition
Institutional investors have recently made changes to their positions in the company. Context Capital Management LLC acquired a new stake in shares of Drugs Made In America Acquisition in the third quarter worth approximately $2,568,000. Clear Street Group Inc. acquired a new position in Drugs Made In America Acquisition during the third quarter worth $2,152,000. Wolverine Asset Management LLC boosted its stake in Drugs Made In America Acquisition by 22.2% during the third quarter. Wolverine Asset Management LLC now owns 1,249,128 shares of the company’s stock worth $12,829,000 after buying an additional 227,222 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in Drugs Made In America Acquisition during the third quarter worth $1,024,000. Finally, Radcliffe Capital Management L.P. boosted its stake in Drugs Made In America Acquisition by 316.7% during the third quarter. Radcliffe Capital Management L.P. now owns 528,100 shares of the company’s stock worth $5,424,000 after buying an additional 401,378 shares during the last quarter.
Drugs Made In America Acquisition Stock Performance
Shares of NASDAQ:DMAA traded down $0.02 during trading on Monday, reaching $10.59. The stock had a trading volume of 177 shares, compared to its average volume of 245,985. The business has a fifty day moving average price of $10.51 and a 200-day moving average price of $10.42. Drugs Made In America Acquisition has a 1-year low of $10.09 and a 1-year high of $10.60.
About Drugs Made In America Acquisition
Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.
Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.
Further Reading
- Five stocks we like better than Drugs Made In America Acquisition
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Drugs Made In America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
-limited-logo-1200x675.png){kind=logo}
